Skip to Main Content

Author Details

Brian J P Huntly
University of Cambridge
1996
137
53
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36350312A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.Clin Cancer Res2023
36350312A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.Clin Cancer Res2023
37580596In vivo screening characterizes chromatin factor functions during normal and malignant hematopoiesis.Nat Genet2023
37802982Distinct and targetable role of calcium-sensing receptor in leukaemia.Nat Commun2023
37872885A guide to epigenetics in leukaemia stem cells.Mol Oncol2023
36577137HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia.Blood2023
37059720Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death.Nat Commun2023
37802982Distinct and targetable role of calcium-sensing receptor in leukaemia.Nat Commun2023
37580596In vivo screening characterizes chromatin factor functions during normal and malignant hematopoiesis.Nat Genet2023
37872885A guide to epigenetics in leukaemia stem cells.Mol Oncol2023
37059720Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death.Nat Commun2023
36577137HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia.Blood2023
34654054KAT2A complexes ATAC and SAGA play unique roles in cell maintenance and identity in hematopoiesis and leukemia.Blood Adv2022
36242770Multiomics data integration to reveal chromatin remodeling and reorganization induced by gene mutational synergy.STAR Protoc2022
35701672Publisher Correction: UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.Nat Genet2022
35439022Targeting AML at the intersection of epigenetics and signaling.Sci Signal2022
35941135Unified classification and risk-stratification in Acute Myeloid Leukemia.Nat Commun2022
35474100Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.Leukemia2022
36465109The RNA editing landscape in acute myeloid leukemia reveals associations with disease mutations and clinical outcome.iScience2022
35134130Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma.Blood2022
34654054KAT2A complexes ATAC and SAGA play unique roles in cell maintenance and identity in hematopoiesis and leukemia.Blood Adv2022
35474100Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.Leukemia2022
35439022Targeting AML at the intersection of epigenetics and signaling.Sci Signal2022
35701672Publisher Correction: UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.Nat Genet2022
36465109The RNA editing landscape in acute myeloid leukemia reveals associations with disease mutations and clinical outcome.iScience2022
35941135Unified classification and risk-stratification in Acute Myeloid Leukemia.Nat Commun2022
36242770Multiomics data integration to reveal chromatin remodeling and reorganization induced by gene mutational synergy.STAR Protoc2022
35134130Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma.Blood2022
32449159Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.Br J Haematol2021
32449159Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.Br J Haematol2021
33951750Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.Br J Haematol2021
34095772Targeting Chromatin Regulation in Acute Myeloid Leukemia.Hemasphere2021
32764680KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.Leukemia2021
33356418Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.J Clin Oncol2021
34556857Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression.Nat Genet2021
34437837Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.Mol Cell2021
34556857Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression.Nat Genet2021
34437837Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.Mol Cell2021
34095772Targeting Chromatin Regulation in Acute Myeloid Leukemia.Hemasphere2021
33951750Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.Br J Haematol2021
33356418Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.J Clin Oncol2021
32764680KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.Leukemia2021
32460828Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting.Trials2020
31958292EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.ESMO Open2020
32179751Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML.Nat Commun2020
31985402Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells.Elife2020
32476069Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications.Curr Oncol Rep2020
32460828Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting.Trials2020
33262182BETs Need Greens: Folate Deficiency and Resistance to MYC-Targeted Therapies.Cancer Discov2020
32868930Dynamic regulation of hypoxia-inducible factor-1α activity is essential for normal B cell development.Nat Immunol2020
  • 1 - 50 of 274

Recommended Authors

Cristina Di Genua
MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital
Career Start Year 2013
Number of shared co-authors 2
Alex Murison
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2012
Number of shared co-authors 3
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Career Start Year 2011
Number of shared co-authors 6
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc.
Career Start Year 2010
Number of shared co-authors 6
Tamara L Lamprecht
St. Jude Children's Research Hospital
Career Start Year 2010
Number of shared co-authors 3
Felicitas Thol
Hannover Medical School
Career Start Year 2007
Number of shared co-authors 21
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 9
Christopher Y Park
NYU Robert I. Grossman School of Medicine
Career Start Year 2006
Number of shared co-authors 4
Richard Koche
Memorial Sloan Kettering Cancer Center
Career Start Year 2005
Number of shared co-authors 6
Aniruddha J Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2004
Number of shared co-authors 4
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 2
Michelle O'Laughlin
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2003
Number of shared co-authors 0
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 18
Gudrun G??hring
Hannover Medical School
Career Start Year 2002
Number of shared co-authors 6
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 3
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 8
Francine E Garrett-Bakelman
University of Virginia
Career Start Year 1999
Number of shared co-authors 4
Lukas D Wartman
Washington University School of Medicine in St. Louis
Career Start Year 1998
Number of shared co-authors 2
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 7
Kolja Eppert
McGill University
Career Start Year 1996
Number of shared co-authors 4
Mar??a D Odero
University of Navarra
Career Start Year 1994
Number of shared co-authors 3
Lucy A Godley
The University of Chicago
Career Start Year 1994
Number of shared co-authors 15
Matthew J Walter
Washington University School of Medicine in St. Louis
Career Start Year 1994
Number of shared co-authors 8
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 25
Timothy A Graubert
Massachusetts General Hospital
Career Start Year 1993
Number of shared co-authors 7
Seishi Ogawa
Kyoto University
Career Start Year 1993
Number of shared co-authors 18
Derek L Stirewalt
Fred Hutchinson Cancer Center
Career Start Year 1992
Number of shared co-authors 2
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 5
Guy Sauvageau
Universite de Montreal
Career Start Year 1988
Number of shared co-authors 3
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 10

Collaborators

Berthold Göttgens
Co-authored papers 13
Emma Gudgin
Co-authored papers 10
Eshwar Meduri
University of Cambridge
Co-authored papers 9
Peter J Campbell
Wellcome Sanger Institute
Co-authored papers 9
Rab K Prinjha
Medicines Research Centre
Co-authored papers 8
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 7
Wendy N Erber
Co-authored papers 6
Clare Pridans
Co-authored papers 5
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 4
Kosuke Yusa
Wellcome Sanger Institute
Co-authored papers 4
David J Adams
Wellcome Sanger Institute
Co-authored papers 4
Scott A Armstrong
Boston Children's Hospital
Co-authored papers 4
Oliver M Dovey
Co-authored papers 4
Anthony D Whetton
Co-authored papers 3
Julio Saez-Rodriguez
Institute of Computational Biomedicine, Heidelberg University
Co-authored papers 3
George Q Daley
Boston Children's Hospital, Harvard Medical School
Co-authored papers 3
Panos Deloukas
William Harvey Research Institute, Queen Mary University of London
Co-authored papers 2
Kenneth C Anderson
Dana Farber Cancer Institute
Co-authored papers 2
Ricky W Johnstone
The University of Melbourne
Co-authored papers 2
Paul A Northcott
St Jude Children's Research Hospital
Co-authored papers 2
Inigo Martincorena
Wellcome Sanger Institute
Co-authored papers 2
Allan Bradley
The Wellcome Trust Sanger Institute
Co-authored papers 2
David P Curley
The Warren Alpert Medical School of Brown University
Co-authored papers 2
Dietger Niederwieser
University of Leipzig
Co-authored papers 2
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Co-authored papers 2
Pedro Madrigal
Co-authored papers 2
Anagha Joshi
University of Bergen
Co-authored papers 2
Adam Butler
Wellcome Sanger Institute
Co-authored papers 2
Vincent J Gnanapragasam
University of Cambridge
Co-authored papers 2
Ultan McDermott
Wellcome Sanger Institute
Co-authored papers 2
Release 1.2